In search of novel clinical and molecular prognostic factors of this rare adult glioma subtype, we analyzed our institutional series of sporadic, intracranial, adult PAs WHO grade I with particular emphasis on the prognostic significance of MGMT promoter methylation status. The gene discussed is MGMT; the disease is central nervous system cancer.